← THE WIRE
1D EOD · SEP 25 CLOSE
● Consumer · Medical DevicesYahoo Finance · AI-written from Yahoo Finance reporting · checked automatically, not by a personWho answers for this

Boston Scientific (BSX) Didn’t Miss on Demand or Devices. A Cyberattack Just Broke Its Guidance.

A cyberattack disrupted Boston Scientific’s guidance despite no reported shortfall in demand or device performance. The setup shifts attention from operating momentum to the duration, cost and disclosure risk of the incident.

Keep this report. See new evidence in Following.
The storyAI-written · 1 min read

Boston Scientific experienced a cyberattack that disrupted its guidance, though underlying demand and device performance remained intact. The attack's affected systems, duration and financial impact remain unclear, as does whether the company withdrew, delayed or revised specific outlook measures.

The contrast lies between intact underlying demand and a guidance problem caused by the attack. Without prior guidance figures, outage timeline or comparison with an earlier forecast, the change in the outlook cannot be quantified.

For Boston Scientific, the direct operational links are evident: an attack could affect order processing, manufacturing, logistics, billing or the company's ability to prepare financial forecasts. The company's FY 2025 revenue was $20.1B, up 19.9% year over year, with a 69.0% gross margin and 14.4% net margin; those figures provide scale but do not establish the incident's current-quarter effect.

Key questions remain about the attack's scope, whether demand remained intact across all device categories, and whether any costs, remediation charges or customer impacts are expected.

The next critical disclosures will be the company's formal update on systems and operations, any revised guidance, and the next earnings release. The key figures will be the duration of disruption, any change to revenue or EPS guidance, incremental remediation costs and evidence of delayed shipments or procedures.

The read · Sep 13

The cyberattack keeps BSX’s demand story intact but moves the near-term risk toward guidance reliability and disruption costs.

The immediate implication is a split read: Boston Scientific's demand and device performance show operational momentum, while the cyberattack creates an unquantified risk to forecasting, execution and incident costs. BSX's FY 2025 revenue growth of 19.9% offers trajectory support, but the disruption's ability to affect that momentum remains uncertain.

What could change this view

A formal update showing no material operational or financial impact would remove the principal downside, while evidence of shipment delays, remediation costs or withdrawn guidance would deepen it.

CoverageSource: Yahoo Finance · Published here SUN, SEP 13 · 3:31 PM ET · the only report in this recordHow this is decided →

Named in the readBSX -1.7%1D EOD · SEP 25
The chart · BSXTradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
Story timeline0 later reports

Earlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.

You are reading this report

No later reports linked yet.

Follow this story to find new evidence in your Following desk.

Since this story · named here, equal weight · 1D EOD-2.5%
SEP 14 · first close after publicationSEP 25

Price context does not establish that the story caused the move.

▲ The case it holds

BSX retains a strong operating backdrop, with FY 2025 revenue of $20.1B and 19.9% year-over-year growth, while the report says demand and devices did not miss.

▼ The case it breaks

The cyberattack has already disrupted guidance.

Receipts
Research, not advice.

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →

SharePost on X
READER EVIDENCEOpens with the recordFollow the story to be told when it moves.